NCT03378063

Stem Cells for Bronchopulmonary Dysplasia

Stem Cells for Bronchopulmonary Dysplasia: a Cohort Study

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Academic / Other
• Sex: All
• Age: 1 Month – 3 Months
• Healthy volunteers: Not accepted

Summary

Very preterm infants are at high risk to develop to bronchopulmonary dysplasia (BPD) for the lack of effective measures to prevent or ameliorate this common and serious disorder. BPD remains a major cause of mortality and lifelong morbidity in preterm infants

Detailed description

Several studies have shown that transplantation of mesenchymal stem cells (MSCs) in immunocompetent animals attenuates lung injury, such as impaired alveolarization, inflammatory response, increased apoptosis, and fibrosis. Human umbilical cord blood (hUCB) is considered a better source of MSCs because of their ready availability and greater proliferative capacity and less antigenicity than other cell types. transplantation of hUCB-derived MSCs should be effective in treating BPD. The safety and efficacy of MSC transplantation for prevention of BPD has not been tested previously, however.

Conditions

• Bronchopulmonary Dysplasia

Interventions

Type	Name	Description
DRUG	transplantation of mesenchymal stem cell	allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants
DRUG	no transplantation of mesenchymal stem cell	MSC transplantation will be not given to preterm infants

Timeline

• Start date: 2017-11-01
• Primary completion: 2022-12-30
• Completion: 2022-12-30
• First posted: 2017-12-19
• Last updated: 2023-05-01

Locations

1 site across 1 country: China